ibudilast has been researched along with Atrophy in 4 studies
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ibudilast showed significant treatment effect on brain atrophy and magnetization transfer ratio (MTR) of normal-appearing brain tissue but not in new/enlarging T2 lesion in the SPRINT-MS randomized clinical trial." | 9.69 | Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis. ( Cohen, JA; Fox, RJ; Mahajan, KR; Nakamura, K; Ontaneda, D; Zheng, Y, 2023) |
| "To investigate the treatment effect of ibudilast on thalamic atrophy more than 96 weeks in the phase 2 trial in progressive(MS Secondary and Primary Progressive Ibudilast NeuroNEXT Trial in Multiple Sclerosis [SPRINT-MS])." | 9.69 | The effect of ibudilast on thalamic volume in progressive multiple sclerosis. ( Bien, H; Brewer, K; Eloyan, A; Klawiter, EC; Nicholson, S; Russo, AW; Tobyne, SM, 2023) |
| " Ibudilast showed significant treatment effect on brain atrophy and magnetization transfer ratio (MTR) of normal-appearing brain tissue but not in new/enlarging T2 lesion in the SPRINT-MS randomized clinical trial." | 5.69 | Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis. ( Cohen, JA; Fox, RJ; Mahajan, KR; Nakamura, K; Ontaneda, D; Zheng, Y, 2023) |
| "To investigate the treatment effect of ibudilast on thalamic atrophy more than 96 weeks in the phase 2 trial in progressive(MS Secondary and Primary Progressive Ibudilast NeuroNEXT Trial in Multiple Sclerosis [SPRINT-MS])." | 5.69 | The effect of ibudilast on thalamic volume in progressive multiple sclerosis. ( Bien, H; Brewer, K; Eloyan, A; Klawiter, EC; Nicholson, S; Russo, AW; Tobyne, SM, 2023) |
| "Determine whether a treatment effect of ibudilast on brain atrophy rate differs between participants with primary (PPMS) and secondary (SPMS) progressive multiple sclerosis." | 5.41 | Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype. ( Bermel, RA; Chase, M; Coffey, CS; Ecklund, DJ; Fedler, JK; Fox, RJ; Goebel, CV; Goodman, AD; Klawiter, EC; Klingner, EA; Naismith, RT; Yankey, J, 2021) |
| "In a phase 2 trial involving patients with progressive multiple sclerosis, ibudilast was associated with slower progression of brain atrophy than placebo but was associated with higher rates of gastrointestinal side effects, headache, and depression." | 5.27 | Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. ( Alvarez, E; Apperson, M; Ashokkumar, A; Barnes, J; Bashir, K; Bermel, RA; Coffey, CS; Cohen, BA; Conwit, R; Coyle, PK; Cudkowicz, ME; Debbins, JP; Delgado, S; Dewitt, LD; Ecklund, D; Flores, A; Fox, RJ; Giesser, BS; Gleason, T; Goldman, MD; Goodman, A; Huang, X; Jagodnik, P; Jubelt, B; Klawiter, EC; Klingner, E; Koepp, M; Krieger, S; Lava, N; Long, JD; Lowe, MJ; Lynch, SG; Matsuda, K; McGovern, M; Moses, H; Naismith, RT; Nakamura, K; Narayanan, S; Natarajan, S; Ontaneda, D; Perumal, JS; Racke, M; Repovic, P; Riley, CS; Sakaie, KE; Severson, C; Shinnar, S; Suski, V; Thoomukuntla, B; Thornell, B; Weinstock-Guttman, B; Yadav, V; Yankey, J; Zabeti, A; Zhou, X, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, K | 2 |
| Zheng, Y | 1 |
| Mahajan, KR | 1 |
| Cohen, JA | 1 |
| Fox, RJ | 3 |
| Ontaneda, D | 2 |
| Nicholson, S | 1 |
| Russo, AW | 1 |
| Brewer, K | 1 |
| Bien, H | 1 |
| Tobyne, SM | 1 |
| Eloyan, A | 1 |
| Klawiter, EC | 3 |
| Goodman, AD | 1 |
| Fedler, JK | 1 |
| Yankey, J | 2 |
| Klingner, EA | 1 |
| Ecklund, DJ | 1 |
| Goebel, CV | 1 |
| Bermel, RA | 2 |
| Chase, M | 1 |
| Coffey, CS | 2 |
| Naismith, RT | 2 |
| Conwit, R | 1 |
| Cudkowicz, ME | 1 |
| Gleason, T | 1 |
| Goodman, A | 1 |
| Matsuda, K | 1 |
| McGovern, M | 1 |
| Ashokkumar, A | 1 |
| Barnes, J | 1 |
| Ecklund, D | 1 |
| Klingner, E | 1 |
| Koepp, M | 1 |
| Long, JD | 1 |
| Natarajan, S | 1 |
| Thornell, B | 1 |
| Debbins, JP | 1 |
| Huang, X | 1 |
| Jagodnik, P | 1 |
| Lowe, MJ | 1 |
| Narayanan, S | 1 |
| Sakaie, KE | 1 |
| Thoomukuntla, B | 1 |
| Zhou, X | 1 |
| Krieger, S | 1 |
| Alvarez, E | 1 |
| Apperson, M | 1 |
| Bashir, K | 1 |
| Cohen, BA | 1 |
| Coyle, PK | 1 |
| Delgado, S | 1 |
| Dewitt, LD | 1 |
| Flores, A | 1 |
| Giesser, BS | 1 |
| Goldman, MD | 1 |
| Jubelt, B | 1 |
| Lava, N | 1 |
| Lynch, SG | 1 |
| Moses, H | 1 |
| Perumal, JS | 1 |
| Racke, M | 1 |
| Repovic, P | 1 |
| Riley, CS | 1 |
| Severson, C | 1 |
| Shinnar, S | 1 |
| Suski, V | 1 |
| Weinstock-Guttman, B | 1 |
| Yadav, V | 1 |
| Zabeti, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis[NCT01982942] | Phase 2 | 255 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To evaluate the activity of ibudilast (100 mg/day) versus placebo at 96 weeks as measured by quantitative magnetic resonance imaging (MRI) analysis for whole brain atrophy using brain parenchymal fraction (BPF), calculated as the ratio of brain parenchymal tissue volume to the total volume contained within the brain surface contour. (NCT01982942)
Timeframe: 96 weeks
| Intervention | ratio (Mean) |
|---|---|
| Ibudilast | -0.00168 |
| Placebo Oral Capsule | -0.00392 |
A magnetization transfer MRI as a marker of brain myelin content including the cerebral cortex could be useful. MT imaging provides access to the restricted protons, which are located in biologically interesting tissue regions.Cortical and normal appearing grey matter MTR correlates strongly with measures of disability such as the multiple sclerosis functional composite score and can show treatment effects. (NCT01982942)
Timeframe: 96 weeks
| Intervention | ratio (Least Squares Mean) |
|---|---|
| Ibudilast | 0.325 |
| Placebo Oral Capsule | 0.247 |
New T1 lesions since baseline as measured by least square mean (90% confidence interval). (NCT01982942)
Timeframe: 96 weeks
| Intervention | lesions (Least Squares Mean) |
|---|---|
| Ibudilast | 0.355 |
| Placebo Oral Capsule | 0.317 |
Safety Measures: percentage of participants who experienced treatment-emergent adverse events, clinically significant abnormal laboratory and electrocardiogram results. (NCT01982942)
Timeframe: 96 weeks
| Intervention | percentage receiving study medication (Number) |
|---|---|
| Ibudilast | 92.2 |
| Placebo Oral Capsule | 88.1 |
Mean retinal nerve fiber layer thickness from baseline measured by Optical coherence tomography (OCT), a non-invasive imaging technique used to obtain high-resolution cross-sectional images of the retina. Increase in thickness is considered improvement. (NCT01982942)
Timeframe: 96 weeks
| Intervention | micrometers (Least Squares Mean) |
|---|---|
| Ibudilast | 83.0 |
| Placebo Oral Capsule | 79.5 |
Diffusion tensor imaging estimates the three-dimensional diffusion of water in brain tissue and has been explored as an outcome in MS. (NCT01982942)
Timeframe: 48 weeks
| Intervention | 10^3/mm^2/s (Least Squares Mean) | |||
|---|---|---|---|---|
| Left axial diffusivity mean | Left radial diffusivity mean | Right axial diffusivity mean | Right radial diffusivity mean | |
| Ibudilast | 0.0001 | -0.0077 | 0.0014 | -0.0029 |
| Placebo Oral Capsule | -0.0006 | 0.0027 | -0.0017 | 0.0046 |
4 trials available for ibudilast and Atrophy
| Article | Year |
|---|---|
Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis.
Topics: Atrophy; Brain; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Chronic | 2023 |
The effect of ibudilast on thalamic volume in progressive multiple sclerosis.
Topics: Atrophy; Bayes Theorem; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive | 2023 |
Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype.
Topics: Adult; Atrophy; Brain; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; P | 2021 |
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.
Topics: Adult; Atrophy; Brain; Depression; Diffusion Tensor Imaging; Disease Progression; Double-Blind Metho | 2018 |